Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Guggenheim

Guggenheim restated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research note released on Friday morning,Benzinga reports.

DYN has been the subject of several other reports. Robert W. Baird started coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research note on Friday, January 10th. Chardan Capital reaffirmed a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Friday, January 10th. JPMorgan Chase & Co. lowered Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. Finally, Raymond James upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $49.91.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $13.72 on Friday. The firm has a market capitalization of $1.40 billion, a P/E ratio of -3.85 and a beta of 1.16. The company has a 50-day simple moving average of $24.03 and a 200-day simple moving average of $32.55. Dyne Therapeutics has a one year low of $13.44 and a one year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, sell-side analysts forecast that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Jason P. Rhodes sold 782 shares of the business’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the completion of the transaction, the director now directly owns 15,962 shares in the company, valued at approximately $528,342.20. The trade was a 4.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carlo Incerti sold 16,500 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The disclosure for this sale can be found here. In the last three months, insiders sold 21,071 shares of company stock valued at $606,476. 20.77% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in DYN. Quantbot Technologies LP bought a new position in Dyne Therapeutics during the third quarter worth about $34,000. Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics during the third quarter worth approximately $36,000. US Bancorp DE raised its position in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Dyne Therapeutics in the third quarter valued at approximately $62,000. Finally, KBC Group NV boosted its stake in shares of Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after buying an additional 978 shares during the period. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.